- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
In pediatric patients (6-17 years):
Tmax: 5 h
T½: 18 h
The pharmacokinetics of guanfacine in children (6 to 12 years) and adolescents (13 to 17 years) with ADHD and adults are comparable.
[SmPC Intuniv]
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| ADHD |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
In cases of severely reduced renal function (creatinine clearance less than 30 ml/min), dose reduction may be needed.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Very common: (>10%): sleepiness (in 41%), headaches (in 27%), lower abdominal pain and fatigue.
Common (1-10%): decreased appetite, weight gain. Depression, anxiety, affect lability, insomnia, insomnia, nightmare, irritability, sedation. Dizziness, lethargy. Bradycardia, (orthostatic) hypotension. Vomiting, diarrhea, nausea, constipation, dry mouth. Skin rash. Bedwetting.
Uncommon (0.1-1%): hypersensitivity. Agitation, hallucination. Convulsion, syncope. First degree AV block, tachycardia, sinus arrhythmia. Whiteness. Asthma. Dyspepsia. Itching. Pollakiuria. Asthenia, chest pain, decreased heart rate. Increased ALT.
Rare (0.01-0.1%: hypersomnia. Hypertension. Malaise.
Very rare (<0.01%): hypertensive encephalopathy (due to an increase in blood pressure after abrupt cessation of treatment).
Also reported: erectile dysfunction.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications in children
Hypersensitivity
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Prior to treatment, assess the patient's increased risk of hypotension, bradycardia, arrhythmia with QT prolongation; To do this, make an inventory of the cardiovascular status, including heart rate, blood pressure and whether there is a family history of sudden death (due to the heart or unexplained). Use caution if you have a history of hypotension, heart block, bradycardia, history of QT prolongation, risk factors for torsade de pointes (such as hypokalaemia) or cardiovascular disease, or if you have a history of syncope or any condition that makes the patient more prone to syncope, such as (orthostatic) hypotension, bradycardia or dehydration. Advise patients to drink a lot. During dose titration, monitor heart rate and blood pressure weekly, at least every 3 months for the first year and then every 6 months (more frequently after dose adjustment). Continue to monitor blood pressure during tapering and after stopping treatment, as an increase in blood pressure may occur.
Check height, weight and BMI before treatment, every 3 months for the first year and every 6 months thereafter.
During dose titration, monitor weekly for symptoms of somnolence, sedation, hypotension and bradycardia. Evaluate at least every 3 months during the first year of treatment and then every 6 months for symptoms of somnolence, sedation, hypotension, bradycardia and weight gain / risk of obesity; monitor more frequently after each dose adjustment.
Use of this medicine has a moderate to severe influence on the ability to drive. Avoid operating machines, driving vehicles and cycling until the patient knows how he or she is responding to treatment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Imidazoline receptor agonists | ||
|---|---|---|
| C02AC01 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Reference
- Shire Pharmaceuticals Ireland Limited, SmPC Intuniv (EU/1/15/1040/001-009) 08-11-2016, www.geneesmiddeleninformatiebank.nl
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
